. 2021 Aug 26;25(19):9306–9318. doi: 10.1111/jcmm.16865

TABLE 3.

The expression of DUSP7, PLD1 and p‐Erk1/2 in the cervical cancer tissue microarray

Parameter	HRAS		DUSP7		PLD1		p‐Erk1/2
	TISS ^a	p value ^b	TISS ^a	p value ^b	TISS ^a	p value ^b	TISS ^a	p value ^b
Age
≤45	5.26 ± 3.34	0.894	3.28 ± 1.33	0.878	5.37 ± 1.07	0.921	6.44 ± 2.41	0.465
>45	6.02 ± 3.79	0.894	3.81 ± 1.54	0.878	5.66 ± 1.15	0.921	7.16 ± 1.25	0.465
Tumour size
≤2 cm	5.25 ± 2.56	0.065	4.35 ± 2.01	0.045	5.15 ± 0.78	0.044	6.43 ± 3.12	0.069
>2 cm	7.11 ± 1.47	0.065	2.72 ± 1.68	0.045	5.97 ± 2.47	0.044	7.52 ± 2.08	0.069
Stage
Ia2+Ib1	4.93 ± 2.112	0.168	3.36 ± 1.38	0.004	5.07 ± 1.11	<0.001	6.29 ± 1.66	0.007
Ib2+IIa	6.72 ± 1.3	0.168	1.99 ± 1.77	0.004	6.03 ± 2.05	<0.001	8.27 ± 3.08	0.007
Grade
1	5.42 ± 3.21	0.661	3.33 ± 1.57	0.804	5.35 ± 1.07	0.094	6.43 ± 1.88	0.558
2+3	6.23 ± 2.90	0.661	2.32 ± 1.90	0.804	5.72 ± 0.78	0.094	7.35 ± 2.22	0.558
LVSI
+	6.12 ± 1.77	0.988	2.09 ± 2.37	0.179	5.84 ± 2.16	0.065	7.68 ± 3.12	0.102
−	5.72 ± 2.31	0.988	3.07 ± 1.31	0.179	5.29 ± 2.33	0.065	6.44 ± 4.01	0.102
Uterus isthmus invasion
+	6.08 ± 1.32	0.878	2.15 ± 1.04	0.243	5.64 ± 1.28	0.153	7.45 ± 2.58	0.754
−	5.75 ± 1.62	0.878	3.22 ± 1.89	0.243	5.49 ± 1.28	0.153	6.57 ± 3.67	0.754
Vaginal invasion
+	6.33 ± 2.41	0.761	1.76 ± 1.98	0.084	5.35 ± 1.34	0.092	7.92 ± 2.22	0.098
−	5.75 ± 1.2	0.761	3.74 ± 1.43	0.084	5.76 ± 1.78	0.092	6.36 ± 1.09	0.098
Parametrial invasion
+	7.92 ± 1.21	0.068	4.25 ± 1.08	0.046	5.88 ± 1.23	0.028	6.16 ± 3.08	0.665
−	6.14 ± 2.03	0.068	2.32 ± 1.48	0.046	5.29 ± 1.15	0.028	5.06 ± 1.44	0.665
LNM
+	7.96 ± 2.16	0.075	1.06 ± 1.22	<0.001	6.98 ± 3.31	<0.001	9.12 ± 1.81	<0.001
−	5.35 ± 1.14	0.075	3.33 ± 1.41	<0.001	5.11 ± 1.83	<0.001	6.33 ± 1.36	<0.001

^{^a}

Specific Index Total Cellular Immunostaining Scoring.

^{^b}

Wilcoxon signed‐rank test.